Source: European Parliament
Priority question for written answer P-002201/2025
to the Commission
Rule 144
Laurent Castillo (PPE)
On 12 March 2025, the United States imposed customs duties of up to 20% on all goods from the European Union.
In response, the Commission initiated a series of countermeasures. The process of adopting these countermeasures was originally scheduled to be completed in mid-April 2025[1] with the entry into force of the act imposing them.
Given the United States’ decision to postpone the entry into force of its universal country-wide tariffs, the EU decided to suspend, for the same period, the planned countermeasures affecting US exports worth EUR 26 billion. Medical devices were not covered by these countermeasures.
However on 8 May 2025[2], the Commission launched a public consultation on a list of US imports liable to be covered by countermeasures by the EU, this time including finished medical devices or apparatus for the manufacture of medical devices produced in the EU.
Can the Commission therefore say:
- 1.What was the reasoning behind this potential U-turn?
- 2.If medical devices were to be included in the countermeasures to US customs duties, what would be the EU’s internal and/or external sources of supply for these products?
- 3.Will these sources of supply be sufficient and enable the health of European citizens to be safeguarded?
Submitted: 2.6.2025